EP1434881A2 - Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer - Google Patents

Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer

Info

Publication number
EP1434881A2
EP1434881A2 EP02766297A EP02766297A EP1434881A2 EP 1434881 A2 EP1434881 A2 EP 1434881A2 EP 02766297 A EP02766297 A EP 02766297A EP 02766297 A EP02766297 A EP 02766297A EP 1434881 A2 EP1434881 A2 EP 1434881A2
Authority
EP
European Patent Office
Prior art keywords
cancer
protein
sequence
nucleic acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02766297A
Other languages
German (de)
English (en)
Other versions
EP1434881A4 (fr
Inventor
Daniel Afar
Natasha Aziz
Kurt C. Gish
Peter A. Hevezi
David H. Mack
Keith E. Wilson
Albert Zlotnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Priority to EP06007721A priority Critical patent/EP1721977A3/fr
Publication of EP1434881A2 publication Critical patent/EP1434881A2/fr
Publication of EP1434881A4 publication Critical patent/EP1434881A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

L'invention concerne des gènes dont l'expression est régulée positivement ou négativement dans des cancers spécifiques ; des procédés et des compositions associées pouvant servir à diagnostiquer et à traiter ces cancers ; et des procédés pouvant servir à identifier des modulateurs de cancers sélectionnés.
EP02766297A 2001-09-17 2002-09-17 Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer Withdrawn EP1434881A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06007721A EP1721977A3 (fr) 2001-09-17 2002-09-17 Méthodes de diagnostic du cancer, compositions et méthodes de criblage des modulateurs du cancer

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US32346901P 2001-09-17 2001-09-17
US323469P 2001-09-17
US32388701P 2001-09-20 2001-09-20
US323887P 2001-09-20
US35066601P 2001-11-13 2001-11-13
US350666P 2001-11-13
US35525702P 2002-02-08 2002-02-08
US35514502P 2002-02-08 2002-02-08
US355145P 2002-02-08
US355257P 2002-02-08
US37224602P 2002-04-12 2002-04-12
US372246P 2002-04-12
PCT/US2002/029560 WO2003025138A2 (fr) 2001-09-17 2002-09-17 Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06007721A Division EP1721977A3 (fr) 2001-09-17 2002-09-17 Méthodes de diagnostic du cancer, compositions et méthodes de criblage des modulateurs du cancer

Publications (2)

Publication Number Publication Date
EP1434881A2 true EP1434881A2 (fr) 2004-07-07
EP1434881A4 EP1434881A4 (fr) 2005-10-26

Family

ID=27559718

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02766297A Withdrawn EP1434881A4 (fr) 2001-09-17 2002-09-17 Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer

Country Status (5)

Country Link
EP (1) EP1434881A4 (fr)
JP (1) JP2005518782A (fr)
AU (1) AU2002330039A1 (fr)
CA (1) CA2459219A1 (fr)
WO (1) WO2003025138A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103579B2 (en) 2013-03-14 2021-08-31 Bristol-Myers Squibb Company Combination of DR5 agonist and anti-PD-1 antagonist and methods of use

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1305409B1 (fr) 2000-06-16 2009-03-11 Biogen Idec MA Inc. Elements de regulation renale et leurs procedes d'utilisation
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2448427C (fr) 2001-06-01 2013-09-24 Biogen, Inc. Molecules et procedes permettant d'empecher la liberation de kim-1
AU2002337442A1 (en) * 2001-09-24 2003-04-07 University Of Aarhus Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ATE364690T1 (de) 2001-11-09 2007-07-15 Proteologics Inc Posh nukleinsäure, polypeptide und darauf bezogene verfahren
US20050014687A1 (en) * 2002-03-19 2005-01-20 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1492885A2 (fr) * 2002-04-05 2005-01-05 University Court of the University of Edinburgh Genes associes a la schizophrenie
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
WO2004001060A2 (fr) 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Identification et modulation d'un recepteur couple aux proteines g (rcpg), rai3, associe a la bronchopneumopathie chronique obstructive (bpco) et a la regulation de nf-$g(k)b et de la e-selectine
GB0215224D0 (en) * 2002-07-01 2002-08-14 Inpharmatica Ltd Protein
JP2006506067A (ja) * 2002-11-12 2006-02-23 ワイス 新規ｐｔｈ反応性遺伝子
JP4689275B2 (ja) 2002-12-30 2011-05-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｋｉｍ−１アンタゴニストおよび免疫系を調節するための使用
JP4462964B2 (ja) * 2003-03-10 2010-05-12 第一三共株式会社 癌特異的抗原を標的とした抗体
EP1615991A4 (fr) 2003-04-03 2007-12-19 Bristol Myers Squibb Co Polynucleotide codant un nouveau variant d'epissage p2x7 humain appele hbmyp2x7v
EP1923401A3 (fr) * 2003-04-14 2008-08-20 Novartis AG Expression génétique associée avec la différenciation des ostéoblastes
WO2004099782A2 (fr) * 2003-05-05 2004-11-18 Bayer Healthcare Ag Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g
WO2005001049A2 (fr) * 2003-06-06 2005-01-06 Diadexus, Inc. Compositions, variants d'epissage et procedes associes a des genes et proteines ovariens specifiques
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
WO2005066363A2 (fr) * 2004-01-09 2005-07-21 Medigen Biotechnology Corporation Gene mg20 specifique du cancer
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
GB0404209D0 (en) * 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
EP1721165B1 (fr) 2004-02-27 2010-03-03 Institut Curie Nouveaux marqueurs de proliferation en pratique clinique et leur utilisation pour le pronostic ou diagnostic du cancer
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP1741792B1 (fr) 2004-04-27 2010-11-03 Takeda Pharmaceutical Company Limited Nouveau ligand de protéine de récepteur conjuguée à une protéine g et utilisation de celui-ci
EP1747467A1 (fr) * 2004-05-11 2007-01-31 Bayer HealthCare AG Diagnostic et therapeutique de maladies associees a la dipeptidyl-peptidase 6 (dpp6)
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
BRPI0513534A (pt) 2004-07-20 2008-05-06 Genentech Inc inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso
DK1781698T3 (en) 2004-07-20 2016-10-03 Genentech Inc COMPOSITIONS AND METHODS FOR THE USE OF Angiopoietin-like-4-PROTEIN
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
KR101213894B1 (ko) 2005-03-02 2012-12-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｔｈ2 매개성 병태를 치료하기 위한 ｋｉｍ-1 항체
CN101198622A (zh) * 2005-04-18 2008-06-11 都柏林伊丽莎白女皇神学院 Toll样受体14（TLR14）及其用途
US7799519B2 (en) * 2005-07-07 2010-09-21 Vanderbilt University Diagnosing and grading gliomas using a proteomics approach
JP2009517479A (ja) * 2005-11-29 2009-04-30 ネバダ キャンサー インスティテュート 骨髄異形成症候群（ｍｄｓ）に関連する増殖性疾患の治療および診断のためのｓａｌｌ４の標的化
SI1957539T1 (sl) 2005-12-08 2013-05-31 Medarex, Inc. Humana monoklonska protitelesa proti protein tirozin kinazi 7 (PTK7) in njihova uporaba
US7678373B2 (en) 2006-02-10 2010-03-16 Genentech, Inc. Anti-FGF19 antibodies and methods using same
TWI397535B (zh) 2006-03-21 2013-06-01 Genentech Inc 包含α5β1拮抗劑之組合治療
WO2008054534A2 (fr) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Systèmes de criblage utilisant le rtp801
EP2026843A4 (fr) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc Utilisations thérapeutiques d'inhibiteurs de rtp801l
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
GB0620705D0 (en) 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
GB0620695D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Composition and methods for the treatment of nurdegenerative disease
EP1932854A1 (fr) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides s'apparentant à une protéine de membrane associée à un lysosome (LAMP), ligands correspondants et leur utilisation dans le cadre de la détection et de la purification de cellules dendritiques plasmacytoïdes humaines
US20100322949A1 (en) * 2007-04-26 2010-12-23 Ludwig Institute For Cancer Research Ltd. Methods for diagnosing and treating astrocytomas
US7994276B2 (en) * 2007-07-27 2011-08-09 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
AU2008299779B2 (en) 2007-08-03 2013-05-16 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
AU2008296927C1 (en) 2007-09-06 2015-08-13 Case Western Reserve University Methods for diagnosing and treating cancers
TWI547503B (zh) 2007-09-26 2016-09-01 建南德克公司 抗α5β1抗體、編碼其之核酸、包含其之組合物及其製造及使用方法
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
JP6067222B2 (ja) 2008-07-15 2017-01-25 ジェネンテック， インコーポレイテッド アントラサイクリン誘導体コンジュゲート、その調製方法及び抗腫瘍化合物としてのその用途
NZ590988A (en) * 2008-08-25 2012-08-31 Janssen Biotech Inc Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
CN102257138B (zh) 2008-10-20 2013-06-19 大日本住友制药株式会社 肿瘤抗原肽及其用途
EP2373690B1 (fr) 2008-12-08 2015-02-11 Compugen Ltd. Anticorps spécifiques du tmem154
AU2014201027B2 (en) * 2008-12-08 2015-11-19 Compugen Ltd. FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
SG10201609416XA (en) 2009-03-25 2016-12-29 Genentech Inc NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
RS62387B1 (sr) 2010-01-29 2021-10-29 Chugai Pharmaceutical Co Ltd Anti-dll3 antitelo
EP2538981B1 (fr) 2010-02-23 2017-12-20 F. Hoffmann-La Roche AG Compositions et procedes de diagnostic et traitement de tumeurs
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
CN114246952A (zh) 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
JP5987053B2 (ja) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングｌｃ−ｍｓ／ｍｓ法
PT2750713E (pt) 2011-10-14 2016-01-20 Genentech Inc Pirrolobenzodiazepinas e conjugados das mesmas
ES2640268T3 (es) 2012-02-15 2017-11-02 Novo Nordisk A/S Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
US9663568B2 (en) 2012-02-15 2017-05-30 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
BR112015002193A2 (pt) 2012-08-02 2017-07-04 Genentech Inc anticorpos anti-etbr e imunoconjugados
KR20150032886A (ko) 2012-08-02 2015-03-30 제넨테크, 인크. 항-etbr 항체 및 면역접합체
PT2906296T (pt) 2012-10-12 2018-06-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
KR101995621B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항-cd22 항체 컨주게이트
JP6270859B2 (ja) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ ピロロベンゾジアゼピン−抗体結合体
CA2887895C (fr) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Conjugues d'anticorps cd19-anti-pyrrolobenzodiazepine
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
RS53818B1 (en) 2012-10-12 2015-06-30 Spirogen Sàrl PIROLOBENZODIAZEPINI I NJIHOVI conjugated
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
CN110452242A (zh) 2012-12-21 2019-11-15 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
KR102057755B1 (ko) 2013-03-13 2019-12-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CA2905181C (fr) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee
KR20160042080A (ko) 2013-08-12 2016-04-18 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
JP6671292B2 (ja) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
WO2015095212A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
MX2016007826A (es) 2013-12-16 2017-03-31 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco.
KR20240029114A (ko) 2014-07-17 2024-03-05 노보 노르디스크 에이/에스 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
WO2016037644A1 (fr) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
EP3191134B1 (fr) 2014-09-12 2019-11-20 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2959689A1 (fr) 2014-09-17 2016-03-24 Genentech, Inc. Pyrrolobenzodiazepines et conjugues a base de disulfure d'anticorps associes
EP3223854A1 (fr) 2014-11-25 2017-10-04 ADC Therapeutics SA Conjugués anticorps-pyrrolobenzodiazépine
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
CN110536703A (zh) 2017-04-20 2019-12-03 Adc治疗有限公司 使用抗axl抗体-药物缀合物的组合疗法
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
RU2020113749A (ru) 2017-09-20 2021-10-20 пиЭйч ФАРМА Ко., ЛТД. Аналоги таиланстатина
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
AR117566A1 (es) 2018-04-02 2021-08-18 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y sus usos
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (fr) 2018-12-10 2021-10-20 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CN115397866A (zh) 2020-03-31 2022-11-25 中外制药株式会社 靶向dll3的多特异性抗原结合分子及其用途
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114113603B (zh) * 2021-06-30 2023-11-17 四川大学华西医院 Cytl1作为胃癌预后标志物的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
AU1724000A (en) * 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US6426186B1 (en) * 2000-01-18 2002-07-30 Incyte Genomics, Inc Bone remodeling genes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRAWUNDER U ET AL: "Interferon-gamma arrests proliferation and causes apoptosis in stromal cell/interleukin-7-dependent normal murine pre-B cell lines and clones in vitro, but does not induce differentiation to surface immunoglobulin-positive B cells." EUROPEAN JOURNAL OF IMMUNOLOGY. FEB 1993, vol. 23, no. 2, February 1993 (1993-02), pages 544-551, XP009053201 ISSN: 0014-2980 *
See also references of WO03025138A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103579B2 (en) 2013-03-14 2021-08-31 Bristol-Myers Squibb Company Combination of DR5 agonist and anti-PD-1 antagonist and methods of use

Also Published As

Publication number Publication date
CA2459219A1 (fr) 2003-03-27
JP2005518782A (ja) 2005-06-30
EP1434881A4 (fr) 2005-10-26
WO2003025138A2 (fr) 2003-03-27
WO2003025138A3 (fr) 2003-05-08
AU2002330039A1 (en) 2003-04-01

Similar Documents

Publication Publication Date Title
EP1434881A2 (fr) Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
KR101446626B1 (ko) 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법
WO2003042661A2 (fr) Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
US7736853B2 (en) Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer
RU2719194C2 (ru) Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов
RU2721130C2 (ru) Оценка активности путей клеточной сигнализации с помощью линейной комбинации(ий) экспрессий генов-мишеней
US20040029114A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
KR102023584B1 (ko) 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법
WO2002086443A2 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
US20040076955A1 (en) Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
MXPA03006617A (es) Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho.
WO2002030268A2 (fr) Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
US20030235820A1 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
WO2001012659A2 (fr) Sequence d'adn humain
US20030068636A1 (en) Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
CN101573453A (zh) 使用生物学途径基因表达分析来预测淋巴结阴性原发性乳腺癌的远处转移的方法
KR20140140069A (ko) 전반적 발달장애의 진단 및 치료용 조성물 및 그 진단 및 치료 방법
KR20140057331A (ko) 유방암의 치료 및 진단을 위한 방법 및 조성물
US20040219579A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
JP2003304888A (ja) 化合物の毒性予測のための方法
KR20070099564A (ko) 급성 골수성 백혈병 환자를 평가하는 방법
JP2003159059A (ja) 痛みに関連する分子の同定及び使用
JP2003156489A (ja) 痛みに関連する分子の同定及び使用
US20020137077A1 (en) Genes regulated in activated T cells
EP1497454A2 (fr) Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040324

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050913

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060419